Sodium channel protein type 1 subunit alpha (SCN1A) (SCN1A; Nav1.1)

Sodium channel protein type 1 subunit alpha (SCN1A) is the pore-forming alpha subunit of the voltage-gated sodium channel Nav1.1, which is essential for generating and propagating electrical signals in neurons and muscle cells[1][5]. Located on chromosome 2, this ion channel controls the flow of sodium ions into cells, directly mediating the depolarizing phase of action potentials and regulating when neurotransmitters are released between neurons[2][5]. SCN1A is one of the most important therapeutic targets in epilepsy, with approximately 900 distinct mutations identified that cause severe seizure disorders including Dravet syndrome, genetic epilepsy and febrile seizures plus (GEFS+), and other forms of childhood epilepsy[3]. Mutations in SCN1A account for a significant proportion of genetically determined seizure disorders, leading to its designation as a "super culprit gene"[3]. Anti-seizure medications target this channel by blocking sodium ion flow to reduce neuronal excitability, though achieving the optimal therapeutic dose remains challenging due to the narrow window between efficacy and side effects[2]. Emerging research suggests that genetic testing for specific SCN1A variants and polymorphisms may enable personalized medicine approaches to optimize drug selection and dosing for individual patients[2]

Other names

Nav1.1NAC1Sodium channel protein brain I subunit alphaVoltage-gated sodium channel subunit alpha Nav1.1GEFSP2HBSCISMEI

Anti-seizure medications treat epilepsy by blocking sodium channels such as Nav1.1 in neurons. The specific mechanism involves: reducing excessive sodium ion influx into neurons; decreasing neuronal excitability to prevent seizure activity; and modulating the balance between GABAergic inhibitory and excitatory signals in the brain. A specific polymorphism (ICS5N+5G>A) may help determine the safest and most effective dosing of anti-seizure medications for individual patients.